Research Analysts’ Weekly Ratings Changes for Progyny (PGNY)

A number of firms have modified their ratings and price targets on shares of Progyny (NASDAQ: PGNY) recently:

• 7/13/2026 – Progyny had its “overweight” rating reaffirmed by KeyCorp.
• 7/8/2026 – Progyny was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/27/2026 – Progyny was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/26/2026 – Progyny was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 6/22/2026 – Progyny had its price target raised by Truist Financial Corporation from $30.00 to $33.00. They now have a “buy” rating on the stock.
• 6/5/2026 – Progyny was downgraded by Zacks Research from “strong-buy” to “hold”.
• 6/2/2026 – Progyny had its price target raised by Bank of America Corporation from $29.00 to $31.00. They now have a “buy” rating on the stock.
• 5/19/2026 – Progyny was upgraded by Canaccord Genuity Group Inc. from “hold” to “buy”. They now have a $30.00 price target on the stock, up from $19.00.
• 5/15/2026 – Progyny had its price target raised by Barclays PLC from $23.00 to $27.00. They now have an “overweight” rating on the stock.

Insider Activity

In other Progyny news, insider Geoffrey Clapp sold 1,530 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the sale, the insider owned 59,117 shares in the company, valued at $1,512,212.86. This trade represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kevin K. Gordon sold 5,500 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total value of $137,445.00. Following the transaction, the director directly owned 9,318 shares in the company, valued at approximately $232,856.82. This represents a 37.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 36,916 shares of company stock worth $939,875. Corporate insiders own 9.90% of the company’s stock.

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.